Barclays’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Barclays’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-22,900	Closed	-$527K	–	7907
2014 Q1	$527K	Buy	22,900 +12,200	+114%	+$177K	﹤0.01%	3909
2013 Q4	$107K	Hold	10,700	–	–	﹤0.01%	5591
2013 Q3	$139K	Buy	+10,700	New	+$169K	﹤0.01%	5359

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Barclays's ECYT Position: Q4 2018 in Review

Barclays sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 34,406 shares — an estimated $611K sold.

Barclays first reported a position in ECYT in Q2 2013 and held it in 22 quarters. The position peaked at $7.23M in Q1 2014. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Barclays reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Barclays sold 34,406 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $611K.
Barclays first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 22 quarters.
Barclays's Endocyte, Inc. Common Stock position peaked at $7.23M in Q1 2014.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Barclays's 13F filing for Q4 2018, filed 14 Feb 2019.